Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CATXNASDAQ:NVNONYSE:NVRONASDAQ:TCMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCATXPerspective Therapeutics$3.32+6.4%$2.31$1.60▼$16.55$246.44M1.111.07 million shs1.40 million shsNVNOenVVeno Medical$3.83+10.1%$3.04$2.03▼$6.48$67.16M0.8115,905 shs668,296 shsNVRONevro$5.85+0.1%$5.85$3.17▼$10.37$224.32M0.81776,481 shs753,602 shsTCMDTactile Systems Technology$10.04-0.7%$11.92$8.61▼$21.10$233.41M1.05264,898 shs255,940 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCATXPerspective Therapeutics-0.32%+15.56%+39.29%+19.54%-77.87%NVNOenVVeno Medical-5.43%-7.20%-0.29%+13.36%-26.74%NVRONevro0.00%0.00%0.00%+1.23%-36.94%TCMDTactile Systems Technology-0.30%+2.12%+2.12%-28.75%-16.52%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCATXPerspective Therapeutics3.0797 of 5 stars4.61.00.00.03.42.50.0NVNOenVVeno Medical0.5015 of 5 stars0.02.00.00.02.50.80.6NVRONevro0.2333 of 5 stars1.00.00.00.00.61.70.6TCMDTactile Systems Technology3.2157 of 5 stars3.01.00.00.02.52.53.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCATXPerspective Therapeutics 3.20Buy$12.63280.27% UpsideNVNOenVVeno Medical 0.00N/AN/AN/ANVRONevro 1.92Reduce$5.36-8.29% DownsideTCMDTactile Systems Technology 2.00Hold$16.0059.36% UpsideCurrent Analyst Ratings BreakdownLatest NVNO, TCMD, CATX, and NVRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025CATXPerspective TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.005/14/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.005/13/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.005/7/2025TCMDTactile Systems TechnologyB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold5/6/2025TCMDTactile Systems TechnologyPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$25.00 ➝ $14.004/7/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $10.003/31/2025CATXPerspective TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/27/2025CATXPerspective TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$16.00 ➝ $15.003/26/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $11.003/19/2025CATXPerspective TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/17/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCATXPerspective Therapeutics$1.43M172.33N/AN/A$2.67 per share1.24NVNOenVVeno MedicalN/AN/AN/AN/A$3.47 per shareN/ANVRONevro$408.52M0.55N/AN/A$8.10 per share0.72TCMDTactile Systems Technology$293.16M0.80$0.71 per share14.21$9.18 per share1.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/11/2025 (Estimated)NVNOenVVeno Medical-$23.52M-$1.18N/AN/AN/AN/A-48.72%-45.96%7/30/2025 (Estimated)NVRONevro-$92.21M-$3.05N/AN/AN/A-16.54%-23.52%-10.83%8/4/2025 (Estimated)TCMDTactile Systems Technology$28.51M$0.6614.3411.95N/A5.79%9.37%6.75%8/4/2025 (Estimated)Latest NVNO, TCMD, CATX, and NVRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025TCMDTactile Systems Technology-$0.07-$0.13-$0.06-$0.13$63.48 million$61.27 million4/30/2025Q1 2025NVNOenVVeno MedicalN/A-$0.22N/A-$0.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCATXPerspective TherapeuticsN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/ANVRONevroN/AN/AN/AN/AN/ATCMDTactile Systems TechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCATXPerspective TherapeuticsN/A9.609.60NVNOenVVeno MedicalN/A22.0122.01NVRONevro0.675.023.76TCMDTactile Systems Technology0.114.363.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCATXPerspective Therapeutics54.66%NVNOenVVeno Medical34.71%NVRONevro95.52%TCMDTactile Systems Technology83.43%Insider OwnershipCompanyInsider OwnershipCATXPerspective Therapeutics3.72%NVNOenVVeno Medical16.00%NVRONevro3.20%TCMDTactile Systems Technology2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCATXPerspective Therapeutics7074.23 million65.21 millionOptionableNVNOenVVeno Medical1917.54 million14.73 millionOptionableNVRONevro1,09038.37 million36.27 millionOptionableTCMDTactile Systems Technology98023.25 million23.36 millionOptionableNVNO, TCMD, CATX, and NVRO HeadlinesRecent News About These CompaniesBank of America Corp DE Raises Stake in Tactile Systems Technology, Inc. (NASDAQ:TCMD)June 4 at 3:24 AM | marketbeat.comNew Data Demonstrates Significant Clinical and Quality-of-Life Benefits of Flexitouch® Plus in Treating Lymphedema Among Head and Neck Cancer SurvivorsJune 3 at 8:00 AM | globenewswire.comMillennium Management LLC Buys New Shares in Tactile Systems Technology, Inc. (NASDAQ:TCMD)June 1, 2025 | marketbeat.comTactile Systems Technology, Inc. (NASDAQ:TCMD) Shares Sold by Nuveen Asset Management LLCMay 29, 2025 | marketbeat.comBNP Paribas Financial Markets Sells 26,955 Shares of Tactile Systems Technology, Inc. (NASDAQ:TCMD)May 29, 2025 | marketbeat.comTactile Systems Technology, Inc. (NASDAQ:TCMD) Shares Bought by Tidal Investments LLCMay 27, 2025 | marketbeat.comMan Group plc Invests $579,000 in Tactile Systems Technology, Inc. (NASDAQ:TCMD)May 27, 2025 | marketbeat.comTactile Systems Technology, Inc. (NASDAQ:TCMD) Stock Position Lessened by D. E. Shaw & Co. Inc.May 26, 2025 | marketbeat.comAmeriprise Financial Inc. Sells 37,472 Shares of Tactile Systems Technology, Inc. (NASDAQ:TCMD)May 26, 2025 | marketbeat.comJane Street Group LLC Purchases 34,846 Shares of Tactile Systems Technology, Inc. (NASDAQ:TCMD)May 25, 2025 | marketbeat.comTactile Medical to Present at Upcoming Investor Conferences in JuneMay 20, 2025 | globenewswire.comDeutsche Bank AG Decreases Stake in Tactile Systems Technology, Inc. (NASDAQ:TCMD)May 19, 2025 | marketbeat.comTactile Systems Technology, Inc. (NASDAQ:TCMD) CFO Sells $29,034.74 in StockMay 15, 2025 | insidertrades.comTactile Systems Technology's (NASDAQ:TCMD) Soft Earnings Don't Show The Whole PictureMay 13, 2025 | finance.yahoo.comTactile Systems Technology (NASDAQ:TCMD) Rating Increased to Hold at B. RileyMay 12, 2025 | marketbeat.comB. Riley Has Negative Estimate for TCMD Q2 EarningsMay 11, 2025 | marketbeat.comDimensional Fund Advisors LP Buys 67,934 Shares of Tactile Systems Technology, Inc. (NASDAQ:TCMD)May 11, 2025 | marketbeat.comWhat is William Blair's Forecast for TCMD Q2 Earnings?May 10, 2025 | marketbeat.comTactile Systems Technology, Inc. (NASDAQ:TCMD) Director Sells $31,911.00 in StockMay 10, 2025 | insidertrades.comFY2025 Earnings Forecast for TCMD Issued By William BlairMay 9, 2025 | marketbeat.comTactile Systems Technology (NASDAQ:TCMD) Cut to "Neutral" at Piper SandlerMay 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVNO, TCMD, CATX, and NVRO Company DescriptionsPerspective Therapeutics NYSE:CATX$3.32 +0.20 (+6.41%) Closing price 04:00 PM EasternExtended Trading$3.34 +0.02 (+0.45%) As of 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.enVVeno Medical NASDAQ:NVNO$3.83 +0.35 (+10.06%) Closing price 04:00 PM EasternExtended Trading$3.86 +0.03 (+0.78%) As of 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. Nevro NYSE:NVRO$5.85 +0.01 (+0.10%) Closing price 04/2/2025Extended Trading$5.85 0.00 (0.00%) As of 04/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.Tactile Systems Technology NASDAQ:TCMD$10.04 -0.07 (-0.69%) Closing price 04:00 PM EasternExtended Trading$10.04 0.00 (-0.05%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company also provides Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
